

Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

20 December 2023

To

The Corporate Relationship Department

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai- 400001

To

National Stock Exchange of India Ltd.,

Exchange Plaza, C-1, Block G,

Bandra Kurla Complex,

Bandra (E)

Mumbai - 400 051

Dear Sir/Madam,

Sub: supporting letter stating details of revision made

Ref. - SCRIP CODE & ID: 530549, SHILPAMED

With respect to the above mentioned subject please find the below revisions made in the revised disclosures pertaining to Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011 submitted on 08 August 2023, 18 August 2023 & 29 August 2023 respectively.

Date of Disclosure:	Revisions made
08 August 2023	Provided the details of lenders and rectification made in the holding details of Mr. Brijgopal Innani
18 August 2023	Provided the details of lenders
29 August 2023	Provided the details of lenders

Kindly take the same on record.

Thanking you,

For and on behalf of

SHILPA MEDICARE LIMITED

Ritu Tiwary

Company Secretary & Compliance Officer



Shilpa Medicare Limited Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

18 August 2023

То

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 To
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 31 of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Ref. - SCRIP CODE & ID: 530549, SHILPAMED

With respect to the above mentioned subject please find the enclosed disclosure under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011 received from Mr. Keshav Bhutada, Mrs. Dharmavati Bhutada & Mr. Madhav Vishnukant Bhutada (members of the Promoter Group) for execution of Non-Disposal Undertaking of 50,00,000 shares of the Company in favor of Catalyst Trusteeship Limited.

Also attached herewith the disclosure pursuant to SEBI Circular dated 07 August 2019 bearing no SEBI/HO/CFD/DCR1/CIR/P/2019/90 with respect to disclosure of reasons for encumbrance by the promoter of listed entity.

Kindly take the same on record.

Thanking you,

For and on behalf of SHILPA MEDICARE LIMITED

Ritu Tiwary

Company Secretary & Compliance Officer

ANNEXURE - 1

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company(TC)

Names of the stock exchanges where the shares of the target company are listed

SHILPA MEDICARE LIMITED

BOMBAY STOCK EXCHANGE NATIONAL STOCK EXCHANGE

17 AUGUST 2023

DHARMAVATI BHUTADA KESHAV BHUTADA MADHAV BHUTADA

Date of reporting

Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked

Details of the creation of encumbrance:

Name ofthe promoter (s) or PACs with him*	Promoter the target (1)	_	Promoter alreadyend (2)	_	Details of event	ts pertaining to encum	brance (3)					Post even holding encumb shares ((2)+(3)) release [/ invocate [(1)-(3)]]	of ered creation / ((2)-(3)] tion
	Number	% of total share capital	Number	% of total share capital	Type of event (creation / release / invocation)	Date of creation/ release/ invocation of encumbrance	Type of encumbrance (pledge / lien/non disposal undertaking/others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity inwhose favor shares encumbered	No of shares	% of total share capital
Dharmavati Bhutada	6207796	7.15%	4207796	4.85%	Creation	17 August 2023	Non-Disposal Undertaking	Towards issue of 35,000 non- convertible debentures of face value Rs.1,00,000 aggregating up	20,00,000	2.30%	Trustee - Catalyst Trusteeship Limited	6207796	7.15%
Keshav Bhutada	2000000	2.30%	500000	0.57%	Creation	17 August 2023	Non-Disposal Undertaking	to Rs. 350,00,00,000 to be issued by Shilpa Pharma Lifesciences Limited and 10,000 non- convertible debentures of face	15,00,000	1.73%	Lenders - ICICI Prudential Corporate Credit Opportunities Fund		2.30%
Madhav Vishnukant Bhutada	2000000	2.30%	500000	0.57%	Creation	17 August 2023	Non-Disposal Undertaking	value Rs.1,00,000 aggregating up to Rs. 100,00,00,000 to be issued by Shilpa Biologicals Private Limited which are its wholly owned subsidiaries	15,00,000	1.73%	AIF-I & OCM Asia Credit I Pte. Ltd.	200000	2.30%

Deepak Kumar Innani	2733960	3.15%	2733960	3.15%	:#E	·		(re-	*	te.	+:	(F)	4.7
Vishnukanth C Bhutada (Huf)	1336130	1.54%	1336130	1.54%	-	*	8	-	•	3	8	8	-
Brijgopal Innani	1174866	1.35%	1174866	1.35%	→ 0.		*		(a)	:-	-		
Om Prakash Inani	2867691	3.30%	2867691	3.30%	138	*	2			=	3		72
Manjulatha Innani	157546	0.18%	157546	0.18%	3	is.	1	A		-		à:	-
Natamal Innani	1131232	1.30%	1131232	1.30%	S#3	5 2 :	7			-	2		-
Ramakant Innani	1497778	1.73%	1497778	1.73%	Sec. 1	•	os:	*	lesi	-	*		-
Kantadevi Inani	2540096	2.93%	2540096	2.93%	-	œ,		× ·	i*€	-			-
Kamal Kishore Innani	165236	0.19%	165236	0.19%	-	(2)	15:	12	12.	-	-		P-
Shakuntalabai Innani	1129186	1.30%	1129186	1.30%	× .		(*)	3. * :	(*)	-	*	E	æ
Tara Devi Innani	1249998	1.44%	1249998	1.44%	3		E	(E)	P. Committee		€	9	4
Triveni Inani	294810	0.34%	294810	0.34%		*	1.0		3 /	=	ta .		ē.
Vishnukanta Inan	1212498	1.40%	1212498	1.40%	9	•) - -		-1	8		Э	×
Ravi Kumar Innani	4006370	4.62%	4006370	4.62%	3	18	·	9-4			-	-	·
Suraj Kumar Innani	3980695	4.59%	0	0	ē	,	2	£.		-	•	(a)	2
Keerti Innani	155021	0.18%	155021	0.18%		S		3	E	3	5	i.	3
Vishnukant Chaturbhuj Bhutada	6365610	7.33%	6365610	7.33%			j.e.		-	-		-	
Priya Innani	180696	0.21%	0	0	à .	-		-	-	*	=	=	100
Namratha Bhutada	22500	0.03%	22500	0.03%	•	•	-	•	9	•		*	4
Sagar Innani	1000000	1.15%	1000000	1.15%		(#C	×	=	8	a	5	= .	3

By Dharmy
Dharmavati Bhutada

Keshav Bhutada

(Nogh)

Madhav Bhutada

Place: Raichur

Date: 17 August 2023

`Annexure - II Disclosure of reasons for encumbrance

(In addition to Annexure - I prescribed by way of circular dated August 05, 2015)

Name of listed company	Shilpa Medicare Limited			
Name of the recognised stock exchanges where the shares	Bombay Stock Exchange			
of the company are listed	National Stock Exchange			
Name of the promoter(s) / PACs whose shares have been	CAMPRAYASIA MANU			
encumbered	OMPRAKASH INANI			
encumbered	KANTADEVI INANI			
	SHAKUNTALABAI INANI			
	NATHMAL INANI			
	RAMAKANT INANI			
	DEEPAK KUMAR INANI			
	BRIJGOPAL INANI			
	VISHNUKANTH CHARURBUJ BHUTADA			
	VISHNUKANTH CHARURBUJ BHUTADA(HUF)			
	DHARMAVATHI VISHUNUKATH BHUTADA TRIVENI INANI			
	KESHAV BHUTADA			
	MADHAV BHUTADA			
	VISHUNUKANTA INANI			
	TARADEVI INANI			
	NAMRATHA BHUTADA			
	SAGAR INNANI			
	MANJULATHA INANI			
	RAVI INANI			
	KAMAL KISHORE INANI			
	KEERTHI INNANI			
Total promoter shareholding in the listed company	No. of shares - 43409715			
	% of total share capital - 50.01%			
Encumbered shares as a % of promoter shareholding	3,92,48,324 eq.sh – 45.21%			
Whether encumbered share is 50% or more of promoter	NO			
shareholding				
Whether encumbered share is 20% or more of total share	Yes			
capital				

Details of all the existing events/ agreements pertaining to encumbrance

		Encumbrance 1	Encumbrance 2
		Deepak Innani	Identified Promoters
disposal u	ncumbrance (pledge, lien, negative lien, non- ndertaking etc. or any other covenant, n, condition orarrangement in the nature of nce)	Pledge	Non Disposal Undertaking
No. and %	of shares encumbered	No. of shares: 600000	No. of shares: 3,92,48,324 eq.sh
		% of total share capital: 0.69%	% of total share capital: 45.21%
Specific details about	Name of the entity in whose favour shares encumbered (X)	Anand Rathi Global Finance Limited	Trustee - Catalyst Trusteeship Limited Lenders - ICICI Prudential Corporate Credit Opportunities Fur AIF-I & OCM Asia Credit I Pte. Ltd.
the encumbr ance	Whether the entity X is a scheduled commercialbank, public financial institution, NBFC or housing finance company? If No, provide the nature of the business of the entity.	NBFC	Debenture Trustee
	Names of all other entities in the agreement	Listed company and itsgroup companies (if any) - NA	Listed company and itsgroup companies (if any) Shilpa Pharma Lifesciences Ltd, Shilpa Biologicals Pvt Ltd and the individual promoter (as described above)
		Other entities (if any) - NA	Other entities (if any) – Catalyst Trusteeship Limited
	Whether the encumbrance is relating to any debt instruments viz. debenture, commercialpaper, certificate of deposit etc.? If yes, providedetails about the instrument, including credit Rating	NO	Yes, it is related to issue of 35,000 non-convertible debentu of face value Rs. 1,00,000 aggregating up to Rs. 350,00,00,0 to be issued by Shilpa Pharma Lifesciences Limited and 10,0 non-convertible debentures of face value Rs. 1,00,000 aggregating up to Rs. 100,00,00,000 to be issued by Shilpa Biologicals Private Limited:-
			The credit rating of Shilpa Pharma Lifesciences Ltd is A(outcome negative) & for Shilpa Biologicals Pvt Ltd is A-ve (outcome negative)

Security	Value of shares on the date of event/	4	13,88,80,19,447		
Cover /	agreement (A)				
Asset	Amount involved (against which shares have	*	450,00,00,000		
Cover	been encumbered) (B)				
	Ratio of A / B	•	3.08		
19	Borrowed amount to be utilized for what purpose –				
	Personal use by promoters and PACs	YES	NO		
	For the benefit of listed company	NO	YES		
	Provide details including amount, purpose of raising money by listed company, schedule for utilization of amount, repayment schedule etc. (a) Any other reason (please specify)		End Use details (i) Towards refinance of existing debt of the Issuer(s); (ii) General Corporate Purposes; (iii) Payment of slump sale consideration (iv) Transaction expenses (v) Intra-company contributions to other members of the Group to repay their existing financial indebtedness		

Signature of Authorized Signatory

Place: Raichur

Date: 17th August 2023